Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Thromb Haemost 2020; 120(01): 184-190
DOI: 10.1055/s-0039-3402055
DOI: 10.1055/s-0039-3402055
Editor's Choice
Thrombosis and Haemostasis 2019 Editor's Choice Papers
1
Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany
2
German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Germany
3
Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre, the Netherlands
,
Anne Rigby
1
Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany
,
4
Liverpool Centre for Cardiovascular Science, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom
5
Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
› Author Affiliations
Further Information
Publication History
18 November 2019
18 November 2019
Publication Date:
13 January 2020 (online)
We would like here to raise a toast to a decade of Editor‘s Choice articles! The first article of this type indeed saw the light in 2010 with a then new collaboration as Editors-in-Chief for Thrombosis & Haemostasis.
Following this good tradition also in the current year, we wish to highlight here hot topic articles of the recent past, which received particular resonance within our reader community, as reflected by their citation, download or Altmetrics score.
-
References
- 1 Paciullo F, Momi S, Gresele P. PCSK9 in haemostasis and thrombosis: possible pleiotropic effects of PCSK9 inhibitors in cardiovascular prevention. Thromb Haemost 2019; 119 (03) 359-367
- 2 Adamkewicz JI, Chen DC, Paz-Priel I. Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays. Thromb Haemost 2019; 119 (07) 1084-1093
- 3 Müller J, Pekrul I, Pötzsch B, Berning B, Oldenburg J, Spannagl M. Laboratory monitoring in emicizumab-treated persons with hemophilia A. Thromb Haemost 2019; 119 (09) 1384-1393
- 4 Knowles LM, Kagiri D, Bernard M, Schwarz EC, Eichler H, Pilch J. Macrophage polarization is deregulated in haemophilia. Thromb Haemost 2019; 119 (02) 234-245
- 5 Elaïb Z, Lopez JJ, Coupaye M. , et al. Platelet functions are decreased in obesity and restored after weight loss: evidence for a role of the SERCA3-dependent ADP secretion pathway. Thromb Haemost 2019; 119 (03) 384-396
- 6 Yao X, Chen W, Liu J. , et al. Deep vein thrombosis is modulated by inflammation regulated via sirtuin 1/NF-κB signalling pathway in a rat model. Thromb Haemost 2019; 119 (03) 421-430
- 7 Li X, Wang SW, Feng Q. , et al. Novel murine model of immune thrombocytopaenia through immunized CD41 knockout mice. Thromb Haemost 2019; 119 (03) 377-383
- 8 Semple JW, Kapur R. The ultimate murine model of immune thrombocytopaenia. Thromb Haemost 2019; 119 (03) 353-354
- 9 Guillamat-Prats R, Rami M, Herzig S, Steffens S. Endocannabinoid signalling in atherosclerosis and related metabolic complications. Thromb Haemost 2019; 119 (04) 567-575
- 10 Van Avondt K, Maegdefessel L, Soehnlein O. Therapeutic targeting of neutrophil extracellular traps in atherogenic inflammation. Thromb Haemost 2019; 119 (04) 542-552
- 11 Joppich M, Weber C, Zimmer R. Using context-sensitive text mining to identify miRNAs in different stages of atherosclerosis. Thromb Haemost 2019; 119 (08) 1247-1264
- 12 Natarelli L, Weber C. Next-generation therapeutic concepts for atherosclerosis: focus on cell specificity and noncoding RNAs. Thromb Haemost 2019; 119 (08) 1199-1201
- 13 Gencer S, van der Vorst EPC, Aslani M, Weber C, Döring Y, Duchene J. Atypical chemokine receptors in cardiovascular disease. Thromb Haemost 2019; 119 (04) 534-541
- 14 Yamakawa K, Murao S, Aihara M. Recombinant human soluble thrombomodulin in sepsis-induced coagulopathy: an updated systematic review and meta-analysis. Thromb Haemost 2019; 119 (01) 56-65
- 15 Kang J, Park KW, Palmerini T. , et al. Racial differences in ischaemia/bleeding risk trade-off during anti-platelet therapy: individual patient level landmark meta-analysis from seven RCTs. Thromb Haemost 2019; 119 (01) 149-162
- 16 Yamakawa K, Gando S, Ogura H. , et al; Japanese Association for Acute Medicine (JAAM) Focused Outcomes Research in Emergency Care in Acute Respiratory Distress Syndrome, Sepsis Trauma (FORECAST) Study Group. Identifying sepsis populations benefitting from anticoagulant therapy: a prospective cohort study incorporating a restricted cubic spline regression model. Thromb Haemost 2019; 119 (11) 1740-1751
- 17 Kearon C, Gu CS, Julian JA. , et al. Pharmacomechanical catheter-directed thrombolysis in acute femoral-popliteal deep vein thrombosis: analysis from a stratified randomized trial. Thromb Haemost 2019; 119 (04) 633-644
- 18 Bikdeli B, Visvanathan R, Jimenez D, Monreal M, Goldhaber SZ, Bikdeli B. Use of prophylaxis for prevention of venous thromboembolism in patients with isolated foot or ankle surgery: a systematic review and meta-analysis. Thromb Haemost 2019; 19 (10) 1686-1694
- 19 Jung H, Yang PS, Sung JH. , et al. Hypertrophic cardiomyopathy in patients with atrial fibrillation: prevalence and associated stroke risks in a nationwide cohort study. Thromb Haemost 2019; 119 (02) 285-293
- 20 Borer JS, Atar D, Marciniak T, Kim MH, Serebruany V. Atrial fibrillation and stroke in patients with hypertrophic cardiomyopathy: important new insights. Thromb Haemost 2019; 119 (03) 355-357
- 21 Steensig K, Olesen KKW, Thim T. , et al. Should the presence or extent of coronary artery disease be quantified in the CHA2DS2-VASc score in atrial fibrillation? A report from the Western Denmark Heart Registry. Thromb Haemost 2018; 118 (12) 2162-2170
- 22 Chao T-F, Liao J-N, Tuan T-C. , et al. Incident co-morbidities in patients with atrial fibrillation initially with a CHA2DS2-VASc score of 0 (males) or 1 (females): implications for reassessment of stroke risk in initially ‘low-risk’ patients. Thromb Haemost 2019; 119 (07) 1162-1170
- 23 Chao TF, Lip GYH, Lin YJ. , et al. Incident risk factors and major bleeding in patients with atrial fibrillation treated with oral anticoagulants: a comparison of baseline, follow-up and delta HAS-BLED scores with an approach focused on modifiable bleeding risk factors. Thromb Haemost 2018; 118 (04) 768-777
- 24 Stemberger M, Kallenbach F, Schmit E. , et al. Impact of adopting population pharmacokinetics for tailoring prophylaxis in haemophilia A patients: a historically controlled observational study. Thromb Haemost 2019; 119 (03) 368-376
- 25 Esteve-Pastor MA, Roldán V, Rivera-Caravaca JM, Ramírez-Macías I, Lip GYH, Marín F. The use of biomarkers in clinical management guidelines: a critical appraisal. Thromb Haemost 2019; 119 (12) 1901-1919
- 26 Zhou D, Ding J, Asmaro K. , et al. Clinical characteristics and neuroimaging findings in internal jugular venous outflow disturbance. Thromb Haemost 2019; 119 (02) 308-318
- 27 Field TS, Weijs B, Curcio A. , et al. Incident atrial fibrillation, dementia and the role of anticoagulation: a population-based cohort study. Thromb Haemost 2019; 119 (06) 981-991
- 28 Hohmann C, Hohnloser SH, Jacob J, Walker J, Baldus S, Pfister R. Non-vitamin K oral anticoagulants in comparison to phenprocoumon in geriatric and non-geriatric patients with non-valvular atrial fibrillation. Thromb Haemost 2019; 119 (06) 971-980
- 29 Quinn TJ, Lane DA. Anticoagulation for atrial fibrillation in older adults-using Big Data for big questions. Thromb Haemost 2019; 119 (06) 855-857
- 30 Ageno W, Haas S, Weitz JI. , et al; GARFIELD-VTE investigators. Characteristics and management of patients with venous thromboembolism: the GARFIELD-VTE Registry. Thromb Haemost 2019; 119 (02) 319-327
- 31 Schellong SM, Goldhaber SZ, Weitz JI. , et al. Isolated distal deep vein thrombosis: perspectives from the GARFIELD-VTE Registry. Thromb Haemost 2019; 19 (10) 1675-1685
- 32 Barco S. What's the matter with distal deep vein thrombosis?. Thromb Haemost 2019; 19 (10) 1547-1549
- 33 Weitz JI, Haas S, Ageno W. , et al. Global Anticoagulant Registry in the Field - Venous Thromboembolism (GARFIELD-VTE). Rationale and design. Thromb Haemost 2016; 116 (06) 1172-1179
- 34 Ageno W, Haas S, Weitz JI. , et al. Upper extremity DVT versus lower extremity DVT: perspectives from the GARFIELD-VTE Registry. Thromb Haemost 2019; 119 (08) 1365-1372
- 35 Duffett L, Kearon C, Rodger M, Carrier M. Treatment of superficial vein thrombosis: a systematic review and meta-analysis. Thromb Haemost 2019; 119 (03) 479-489
- 36 Sugiura-Ogasawara M, Ebara T, Matsuki T. , et al; and the Japan Environment & Children's Study (JECS) Group. Endometriosis and recurrent pregnancy loss as new risk factors for venous thromboembolism during pregnancy and post-partum: the JECS birth cohort. Thromb Haemost 2019; 119 (04) 606-617
- 37 Radin M, Schreiber K, Sciascia S. , et al. Prevalence of antiphospholipid antibodies negativisation in patients with antiphospholipid syndrome: a long-term follow-up multicentre study. Thromb Haemost
- 38 Grilz E, Posch F, Königsbrügge O. , et al. Association of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio with the risk of thromboembolism and mortality in patients with cancer. Thromb Haemost 2018; 118 (11) 1875-1884
- 39 Aharon A, Sabbah AR, Issman L. , et al. Effects of low- and high-dose chemotherapy agents on thrombogenic properties of extracellular vesicles derived from breast cancer cell lines. Thromb Haemost 2018; 118 (03) 480-489
- 40 Kraaijpoel N, Di Nisio M, Mulder FI. , et al. Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer Study. Thromb Haemost 2018; 118 (08) 1439-1449
- 41 Kraaijpoel N, van Es N, Raskob GE. , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE Study. Thromb Haemost 2018; 118 (07) 1270-1278
- 42 Pelland-Marcotte MC, Pole JD, Kulkarni K. , et al. Thromboembolism incidence and risk factors in children with cancer: a population-based cohort study. Thromb Haemost 2018; 118 (09) 1646-1655
- 43 Campello E, Henderson MW, Noubouossie DF, Simioni P, Key NS. Contact system activation and cancer: new insights in the pathophysiology of cancer-associated thrombosis. Thromb Haemost 2018; 118 (02) 251-265
- 44 Kraaijpoel N, van Es N, Bleker SM. , et al. Clinical impact and course of anticoagulant-related major bleeding in cancer patients. Thromb Haemost 2018; 118 (01) 174-181
- 45 Carmona-Bayonas A, Jimenez-Fonseca P, Garrido M. , et al. Multistate models: accurate and dynamic methods to improve predictions of thrombotic risk in patients with cancer. Thromb Haemost 2019; 119 (11) 1849-1859
- 46 Pelland-Marcotte M-C, Tole S, Pechlivanoglou P, Brandão LR. Effectiveness and safety of primary thromboprophylaxis in children with cancer: a systematic review of the literature and network meta-analysis. Thromb Haemost
- 47 Sumaya W, Geisler T, Kristensen SD, Storey RF. Dual antiplatelet or dual antithrombotic therapy for secondary prevention in high-risk patients with stable coronary artery disease?. Thromb Haemost 2019; 19 (10) 1583-1589
- 48 Pastori D, Eikelboom JW, Anand SS. , et al. Management of patients with asymptomatic and symptomatic carotid artery disease: update on anti-thrombotic therapy. Thromb Haemost 2019; 119 (04) 576-585
- 49 Cohen AT, Agnelli G, Buller HR. , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY trial. Thromb Haemost 2019; 119 (03) 461-466
- 50 Franchi F, Rollini F, Garcia E. , et al. Effects of edoxaban on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel: results of the EDOX-APT Study. Thromb Haemost 2019; 120 (02) 83-93
- 51 Gorog DA. Understanding the effects of NOAC combined with antiplatelet therapy on clot kinetics. Thromb Haemost
- 52 Hohnloser SH, Basic E, Nabauer M. Changes in oral anticoagulation therapy over one year in 51,000 atrial fibrillation patients at risk for stroke: a practice-derived study. Thromb Haemost 2019; 119 (06) 882-893
- 53 Weitz JI, Chan NC. Long-term management of venous thromboembolism: lessons from EINSTEIN CHOICE and other extension trials. Thromb Haemost 2019; 119 (05) 689-694
- 54 De Caterina R, Ageno W, Agnelli G. , et al. The non-vitamin K antagonist oral anticoagulants in heart disease: section V-special situations. Thromb Haemost 2019; 119 (01) 14-38
- 55 Pritchett RV, Bem D, Turner GM. , et al. Improving the prescription of oral anticoagulants in atrial fibrillation: a systematic review. Thromb Haemost 2019; 119 (02) 294-307
- 56 Fanikos J, Murwin D, Gruenenfelder F. , et al. Global use of idarucizumab in clinical practice: outcomes of the RE-VECTO Surveillance Program. Thromb Haemost 2019; 120 (02) 83-93
- 57 Fauchier L, Potpara T. Idarucizumab for reversion of anticoagulant effect in daily practice. Thromb Haemost
- 58 Attard C, Ignjatovic V. Primary thromboprophylaxis in children with cancer: a road less travelled. Thromb Haemost 2019 119. (12)
- 59 Agnelli G, Becattini C, Bauersachs R. , et al; Caravaggio Study Investigators. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio Study. Thromb Haemost 2018; 118 (09) 1668-1678
- 60 O'Brien SH, Li D, Mitchell LG. , et al. PREVAPIX-ALL: apixaban compared to standard of care for prevention of venous thrombosis in paediatric acute lymphoblastic leukaemia (ALL)-rationale and design. Thromb Haemost 2019; 119 (05) 844-853